A Study of CIN-107 in Patients With Uncontrolled Hypertension (HALO)

  • participants needed
  • sponsor
    CinCor Pharma, Inc.
Updated on 30 September 2022
Enion Hampton
Primary Contact
CinCor Site 57 (7.2 mi away) Contact
+61 other location


This is a Phase 2, randomized, multicenter study to evaluate the efficacy and safety of multiple dose strengths of CIN-107 in the treatment of patients with uncontrolled hypertension.

Condition Uncontrolled Hypertension
Treatment Placebo, CIN-107
Clinical Study IdentifierNCT05137002
SponsorCinCor Pharma, Inc.
Last Modified on30 September 2022

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note